ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
5.65
-0.73 (-11.44%)
Aug 20, 2026, 2:36 PM EDT - Market open
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $33.66M in the quarter ending June 30, 2026, with 114.15% growth. This brings the company's revenue in the last twelve months to $116.93M, up 4.08% year-over-year. In the year 2025, ARS Pharmaceuticals had annual revenue of $84.28M, down -5.46%.
Revenue (ttm)
$116.93M
Revenue Growth
+4.08%
P/S Ratio
4.89
Revenue / Employee
$735,390
Employees
159
Market Cap
561.88M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 84.28M | -4.87M | -5.46% |
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| MiMedx Group | 355.17M |
| Arvinas | 316.70M |
| Valneva SE | 163.30M |
| Verastem | 87.53M |
| OmniAb | 38.46M |
| Prime Medicine | 4.07M |
| Altimmune | 31.00K |
SPRY News
- 3 days ago - Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026 - Newsfile Corp
- 4 days ago - ARS Pharmaceuticals reports Q2 EPS (63c), consensus (49c) - TheFly
- 4 days ago - ARS Pharmaceuticals sees cash flow break-even by end of 2027 - TheFly
- 4 days ago - ARS Pharmaceuticals names Meg Smith as Chief Commercial Officer - TheFly
- 5 days ago - Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 6 days ago - ARS Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 6 days ago - ARS Pharmaceuticals Earnings release: Q2 2026 - Filings
- 6 days ago - ARS Pharmaceuticals Quarterly report: Q2 2026 - Filings